Switzerland's Oculis Q1 net loss narrows, cash rises

Oculis Holding AG

11/05/2026 21:13

Overview

Switzerland biopharma firm's Q1 net loss narrowed yr/yr as DIAMOND program neared completion

Cash and short-term investments rose to CHF 222 mln

Operating expenses declined due to reduced external spending as DIAMOND program approached completion

Outlook

Oculis expects topline results for OCS-01 Phase 3 DME trials in June 2026

Company anticipates Licaminlimab PREDICT-1 topline results around year-end 2026

Oculis says cash runway extends into 2H 2029

Result Drivers

R&D SPENDING - Lower research and development expenses driven by reduced external service provider costs as DIAMOND program neared completion

WARRANT LIABILITY - Decrease in net loss mainly due to lower non-cash fair value loss on warrant liabilities and favorable currency movements

ADMIN COSTS - General and administrative expenses rose due to increased share-based compensation expense

Company press release: ID:nGNEYDfMk

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-CHF 0.49
Q1 Net Income
-CHF 28.85 mln
Q1 Operating Expenses
-CHF 21.94 mln
Q1 Operating Income
CHF 209,000
Q1 Pretax Profit
-CHF 28.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Oculis Holding AG is $49.50, about 51.7% above its May 8 closing price of $32.64

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)